GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Gross-Profit-to-Asset %

Ultimovacs ASA (OSL:ULTI) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Ultimovacs ASA's annualized Gross Profit for the quarter that ended in Dec. 2023 was kr0.00 Mil. Ultimovacs ASA's average Total Assets over the quarter that ended in Dec. 2023 was kr368.39 Mil. Therefore, Ultimovacs ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Ultimovacs ASA Gross-Profit-to-Asset % Historical Data

The historical data trend for Ultimovacs ASA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Gross-Profit-to-Asset % Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only - - - - -

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultimovacs ASA's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Ultimovacs ASA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Gross-Profit-to-Asset % falls into.



Ultimovacs ASA Gross-Profit-to-Asset % Calculation

Ultimovacs ASA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (509.672+349.039)/ 2 )
=0/429.3555
=0.00 %

Ultimovacs ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (387.742+349.039)/ 2 )
=0/368.3905
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Ultimovacs ASA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (OSL:ULTI) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.